SCHEMBL882256

SCHEMBL882256

C=C/C=N\C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2241562 1.00
SCHEMBL2241560 1.00
SCHEMBL10066350 0.74
SCHEMBL7992428 0.74
SCHEMBL8077995 0.72
SCHEMBL21191554 0.72
SCHEMBL17540027 0.72
SCHEMBL8280822 0.71
SCHEMBL242680 0.71
SCHEMBL14639585 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3383860-B1 APELIN RECEPTOR AGONISTS AND METHODS OF USE BRISTOL MYERS SQUIBB CO (US) 2021-01-20 EP disclosed
WO-2020146532-A1 METALLOENZYME INHIBITOR COMPOUNDS SPARKS STEVEN (US) 2020-07-16 WO disclosed
US-10656522-B2 Composition for forming fine resist pattern and pattern forming method using same AZ ELECTRONIC MATERIALS (LUXEMBOURG) S.A.R.L. (LU) 2020-05-19 US disclosed
US-9889136-B2 Tetrahydropyridopyrimidine compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-02-13 US disclosed
US-20170305859-A1 An Anticonvulsant Compound ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE (GB) 2017-10-26 US disclosed
WO-2017165640-A1 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDINE-5-CARBOXAMIDES AS APJ AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-28 WO disclosed
US-20170267695-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-09-21 US disclosed
WO-2017106396-A1 HETEROARYLHYDROXYPYRIMIDINONES AS AGONISTS OF THE APJ RECEPTOR BRISTOL-MYERS SQUIBB COMPANY (US) 2017-06-22 WO disclosed
WO-2017096130-A1 APELIN RECEPTOR AGONISTS AND METHODS OF USE BRISTOL-MYERS SQUIBB COMPANY (US) 2017-06-08 WO disclosed
US-9624194-B2 Heteroaryl compounds as sodium channel blockers PURDUE PHARMA L.P. (US) 2017-04-18 US disclosed
WO-2013102431-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-11 WO disclosed
WO-2013023000-A2 SMALL MOLECULE COMPOUNDS THAT CONTROL MAMMAL-PATHOGENIC NEMATODES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-02-14 WO disclosed
WO-2013022985-A2 SMALL MOLECULE COMPOUNDS FOR THE CONTROL OF NEMATODES BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH (US) 2013-02-14 WO disclosed
WO-2013022996-A2 THE UTILITY OF NEMATODE SMALL MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2013-02-14 WO disclosed
WO-2012040040-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-03-29 WO disclosed
US-7772431-B1 Performance of energy storage devices: potential areas for dendritic chemistry involvement NEWKOME GEORGE R 2010-08-10 US disclosed
EP-2013202-B1 SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE JANSSEN PHARMACEUTICA NV (BE) 2010-06-16 EP disclosed
WO-2008001070-A1 PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-01-03 WO disclosed
US-20070054903-A1 Bis-aryl kinase inhibitors and method AMGEN INC. (US) 2007-03-08 US disclosed
US-20070027156-A1 Crf antagonists and heterobicyclic compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-01 US disclosed